期刊
CELL REPORTS
卷 35, 期 6, 页码 -出版社
CELL PRESS
DOI: 10.1016/j.celrep.2021.109109
关键词
-
类别
资金
- Xiamen University COVID-19 Emergency Fund
- Bill and Melinda Gates Foundation [OPP1170236, INV-004923]
- Bill and Melinda Gates Foundation [OPP1170236, INV-004923] Funding Source: Bill and Melinda Gates Foundation
The study found that neutralizing antibody responses to SARS-CoV-2 have diverse B cell receptor repertoires and convergent epitope targeting, providing important guidance for effective vaccine design.
It is unclear whether individuals with enormous diversity in B cell receptor repertoires are consistently able to mount effective antibody responses against SARS-CoV-2. We analyzed antibody responses in a cohort of 55 convalescent patients and isolated 54 potent neutralizing monoclonal antibodies (mAbs). While most of the mAbs target the angiotensin-converting enzyme 2 (ACE2) binding surface on the receptor binding domain (RBD) of SARS-CoV-2 spike protein, mAb 47D1 binds only to one side of the receptor binding surface on the RBD. Neutralization by 47D1 is achieved independent of interfering RBD-ACE2 binding. A crystal structure of the mAb-RBD complex shows that the IF motif at the tip of 47D1 CDR H2 interacts with a hydrophobic pocket in the RBD. Diverse immunoglobulin gene usage and convergent epitope targeting characterize neutralizing antibody responses to SARS-CoV-2, suggesting that vaccines that effectively present the receptor binding site on the RBD will likely elicit neutralizing antibody responses in a large fraction of the population.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据